Different inflammatory responses induced by three LDL-lowering apheresis columns

Journal of Clinical Apheresis

Volumn 24, Issue 6, 2009, Pages 247-253

  Hovland, Anders ^a,b   Hardersen, Randolf ^a   Sexton, Joe ^c   Mollnes, Tom Eirik ^a   Lappegård, Knut Tore ^a,b  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Apheresis; Cytokines; Familial hypercholesterolemia; Inflammation; LDL cholesterol

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHEMOKINE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GROWTH FACTOR; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR BB; RANTES; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADSORPTION KINETICS; ADULT; APHERESIS; ARTICLE; BLOOD FILTRATION; CASE REPORT; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT LECTIN PATHWAY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEVICE THERAPY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HEMADSORPTION; HETEROZYGOTE; HUMAN; INFLAMMATORY DISEASE; INTERMETHOD COMPARISON; MALE;

ADULT; BLOOD COMPONENT REMOVAL; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; COMPLEMENT MEMBRANE ATTACK COMPLEX; CROSS-OVER STUDIES; CYTOKINES; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INFLAMMATION; MALE; MIDDLE AGED;

EID: 71849089404     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20223     Document Type: Article

References (33)

1. Thompson GR. LDL apheresis. Atherosclerosis 2003;167:1-13.
2. Neil HA, Huxley RR, Hawkins MM, Durrington PN, Betteridge DJ, Humphries SE. Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study. Atherosclerosis 2003;170:73-78.
3. Mabuchi H, Koizumi J, Shimizu M, Kajinami K, Miyamoto S, Ueda K, Takegoshi T. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 1998;82:1489-1495.
4. Kroon AA, Aengevaeren WR, van der WT, Uijen GJ, Reiber JH, Bruschke AV, Stalenhoef AF. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996;93:1826-1835.
5. Distelmaier K, Adlbrecht C, Jakowitsch J, Winkler S, Dunkler D, Gerner C, Wagner O, Lang IM, Kubicek M. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost 2009;102:564-572.
6. Wu G, Hu W, Shahsafaei A, Song W, Dobarro M, Sukhova GK, Bronson RR, Shi GP, Rother RP, Halperin JA, Qin X. Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ Res 2009;104:550-558.
7. Leung VW, Yun S, Botto M, Mason JC, Malik TH, Song W, Paixao-Cavalcante D, Pickering MC, Boyle JJ, Haskard DO. Decay-accelerating factor suppresses complement C3 activation and retards atherosclerosis in low-density lipoprotein receptor-deficient mice. Am J Pathol 2009;175:1757-1767.
8. Yun S, Leung VW, Botto M, Boyle JJ, Haskard DO. Brief report: accelerated atherosclerosis in low-density lipoprotein receptor-deficient mice lacking the membrane-bound complement regulator CD59. Arterioscler Thromb Vasc Biol 2008;28:1714-1716.
9. Fadul JE, Alarabi AA, Wikstrom B, Danielson BG, Nilsson B. Identification of complement activators and elucidation of the fate of complement activation products during extracorporeal plasma purification therapy. J Clin Apher 1998;13:167-173. (Pubitemid 29029276)
10. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695.
11. Aukrust P, Halvorsen B, Yndestad A, Ueland T, Oie E, Otterdal K, Gullestad L, Damas JK. Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol 2008;28:1909-1919.
12. Wang Y, Blessing F, Walli AK, Uberfuhr P, Fraunberger P, Seidel D. Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins - reduction of circulating proinflammatory and procoagulatory markers. Atherosclerosis 2004;175:145-150. (Pubitemid 38746921)
13. Julius U, Metzler W, Pietzsch J, Fassbender T, Klingel R. Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP. Int J Artif Organs 2002;25:1180-1188. (Pubitemid 36109104)
14. Hershcovici T, Schechner V, Orlin J, Harell D, Beigel Y. Effect of different LDL-apheresis methods on parameters involved in atherosclerosis. J Clin Apher 2004;19:90-97. (Pubitemid 39006614)
15. Kobayashi S, Oka M, Moriya H, Maesato K, Okamoto K, Ohtake T. LDL-apheresis reduces P-selectin, CRP and fibrinogen - possible important implications for improving atherosclerosis. Ther Apher Dial 2006;10:219-223.
16. Schechner V, Shapira I, Berliner S, Comaneshter D, Hershcovici T, Orlin J, Zeltser D, Rozenblat M, Lachmi K, Hirsch M, Beigel Y. Significant dominance of fibrinogen over immunoglobulins, C-reactive protein, cholesterol and triglycerides in maintaining increased red blood cell adhesiveness/aggregation in the peripheral venous blood: a model in hypercholesterolaemic patients. Eur J Clin Invest 2003;33:955-961. (Pubitemid 37421593)
17. Kobayashi A, Nakatani M, Furuyoshi S, Tani N. In vitro evaluation of dextran sulfate cellulose beads for whole blood infusion low-density lipoprotein-hemoperfusion. Ther Apher 2002;6:365-371.
18. Otto C, Kern P, Bambauer R, Kallert S, Schwandt P, Parhofer KG. Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia. Artif Organs 2003;27:1116-1122. (Pubitemid 38037567)
19. Kojima S, Shida M, Yokoyama H. Changes in C-reactive protein plasma levels during low-density lipoprotein apheresis. Ther Apher Dial 2003;7:431-434. (Pubitemid 37082032)
20. Klingel R, Mausfeld P, Fassbender C, Goehlen B. Lipid-filtration - safe and effective methodology to perform lipid-apheresis. Transfus Apher Sci 2004;30:245-254. (Pubitemid 38698339)
21. Mollnes TE, Lea T, Froland SS, Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985;22:197-202. (Pubitemid 15016794)
22. Dihazi H, Koziolek MJ, Sollner T, Kahler E, Klingel R, Neuhoff R, Strutz F, Mueller GA. Protein adsorption during LDL-apheresis: proteomic analysis. Nephrol Dial Transplant 2008;23:2925-2935.
23. Muscari A, Massarelli G, Bastagli L, Poggiopollini G, Tomassetti V, Drago G, Martignani C, Pacilli P, Boni P, Puddu P. Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. Eur Heart J 2000;21:1081-1090. (Pubitemid 30352992)
24. Nijmeijer R, Krijnen PA, Assink J, Klaarenbeek MA, Lagrand WK, Veerhuis R, Visser CA, Meijer CJ, Niessen HW, Hack CE. C-reactive protein and complement depositions in human infarcted myocardium are more extensive in patients with reinfarction or upon treatment with reperfusion. Eur J Clin Invest 2004;34:803-810. (Pubitemid 39657927)
25. Speidl WS, Exner M, Amighi J, Kastl SP, Zorn G, Maurer G, Wagner O, Huber K, Minar E, Wojta J, Schillinger M. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J 2005;26:2294-2299. (Pubitemid 41541394)
26. Verma S, Szmitko PE, Yeh ET. C-reactive protein: structure affects function. Circulation 2004;109:1914-1917. (Pubitemid 38544477)
27. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207.
28. Otto C, Berster J, Otto B, Parhofer KG. Effects of two whole blood systems (DALI and Liposorber D) for LDL apheresis on lipids and cardiovascular risk markers in severe hypercholesterolemia. J Clin Apher 2007;22:301-305. (Pubitemid 351219763)
29. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006;86:515-581.
30. Koh SJ, Kim JY, Hyun YJ, Park SH, Chae JS, Park S, Kim JS, Youn JC, Jang Y, Lee JH. Association of serum RANTES concentrations with established cardiovascular risk markers in middle-aged subjects. Int J Cardiol 2009;132:102-108.
31. Lappegard KT, Bergseth G, Riesenfeld J, Pharo A, Magotti P, Lambris JD, Mollnes TE. The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent. J Biomed Mater Res A 2008;87:129-135.
32. Julius U, Parhofer KG, Heibges A, Kurz S, Klingel R, Geiss HC. Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis - comparison of performance characteristics with DALI and lipid filtration. J Clin Apher 2007;22:215-223. (Pubitemid 47320236)
33. Poli L, Busnach G. Whole blood selective LDL-apheresis: a comparison of two different adsorbers. Int J Artif Organs 2006;29:726-732. (Pubitemid 44262941)